Jie Wang

Overview:

I completed my hematology/oncology fellowship training and Masters of Science in Translational Research at the University of Pennsylvania.  I am dedicated to the treatment of lymphoma and have developed a specific interest in the T cell lymphomas.  I am inspired by the opportunity for the development of new treatments, and aspire to be a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy.  My recent research has focused on the development of immune therapies for the treatment of T cell malignancies.  I believe that novel approaches are needed in this group of diseases. 

Positions:

Assistant Professor of Medicine

Medicine, Hematological Malignancies
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2010

The University of Chicago, Pritzker School of Medicine

Internal Medicine Internship and Residency

University of Michigan, Ann Arbor

Hematology/Oncology Fellowship

University of Pennsylvania, School of Medicine

Lymphoma Translational Research Fellowship

University of Pennsylvania, School of Medicine

Grants:

A Phase I, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A bispecific DART Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms

Administered By
Duke Cancer Institute
Awarded By
MacroGenics, Inc.
Role
Principal Investigator
Start Date
End Date

: A PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF DS-3201B IN SUBJECTS WITH LYMPHOMAS

Administered By
Duke Cancer Institute
Awarded By
Daiichi Sankyo Inc
Role
Principal Investigator
Start Date
End Date

Publications:

A Cautionary Tale: Florid Splenic γδ T-cell Proliferation and False-Positive T-cell Clonality by PCR Leads to a Grave Misdiagnosis.

The discrimination of benign from malignant lymphoproliferative disorders is sometimes difficult because there can be overlap in their histological and immunophenotypic features. In such situations, molecularly based clonality testing is often used to discriminate benign (polyclonal) from malignant (monoclonal) processes. Clonality testing by polymerase chain reaction (PCR) has a number of pitfalls that may result in spurious results. Here we report the case of a woman diagnosed by 2 major academic institutions with hepatosplenic T-cell lymphoma based on a dense infiltration of the spleen by a γδ T-cell population with mild cytologic atypia, resulting in expansion of the splenic red pulp, and a positive T-cell receptor clonality test by PCR. There was likewise mild involvement of the liver and bone marrow by the "atypical" T-cell population. Close attention to her uncharacteristically well clinical appearance led to repeat T-cell receptor clonality testing using next-generation sequencing. Definitive demonstration of polyclonality by this test showed that she in fact did not have hepatosplenic T-cell lymphoma but rather a reactive condition, and allogeneic stem cell transplantation could be safely avoided. As molecular clonality testing is widely used in the practice of hematology, this case brings attention to the pitfalls of clonality testing by PCR that practitioners may encounter. It is therefore a cautionary tale highlighting the need for critical interpretation of test results in full clinical context.
Authors
MLA Citation
Hwang, Joyce K., et al. “A Cautionary Tale: Florid Splenic γδ T-cell Proliferation and False-Positive T-cell Clonality by PCR Leads to a Grave Misdiagnosis.Clinical Lymphoma, Myeloma & Leukemia, vol. 21, no. 10, Oct. 2021, pp. e748–51. Epmc, doi:10.1016/j.clml.2021.05.010.
URI
https://scholars.duke.edu/individual/pub1485901
PMID
34158266
Source
epmc
Published In
Clinical Lymphoma, Myeloma & Leukemia
Volume
21
Published Date
Start Page
e748
End Page
e751
DOI
10.1016/j.clml.2021.05.010

Complete Response of a Young Woman With MYD88WT Bing-Neel Syndrome on Ibrutinib Monotherapy Following a Single Cycle of B Hyper-CVAD/IT MTX.

Authors
Pabon, CM; Neff, JL; Forns, TE; Wang, J
MLA Citation
Pabon, Cindy M., et al. “Complete Response of a Young Woman With MYD88WT Bing-Neel Syndrome on Ibrutinib Monotherapy Following a Single Cycle of B Hyper-CVAD/IT MTX.Clin Lymphoma Myeloma Leuk, vol. 20, no. 11, Nov. 2020, pp. e809–12. Pubmed, doi:10.1016/j.clml.2020.06.004.
URI
https://scholars.duke.edu/individual/pub1451623
PMID
32660904
Source
pubmed
Published In
Clin Lymphoma Myeloma Leuk
Volume
20
Published Date
Start Page
e809
End Page
e812
DOI
10.1016/j.clml.2020.06.004